{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:58:00Z","timestamp":1783745880040,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008880","name":"Kanae Foundation for the Promotion of Medical Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s13730-018-0332-3","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T11:02:19Z","timestamp":1526382139000},"page":"217-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Gemcitabine-induced thrombotic microangiopathy with nephrotic syndrome"],"prefix":"10.1007","volume":"7","author":[{"given":"Daisuke","family":"Katagiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-6787","authenticated-orcid":false,"given":"Fumihiko","family":"Hinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"332_CR1","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1002\/cncr.20290","volume":"100","author":"BD Humphreys","year":"2004","unstructured":"Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100:2664\u201370.","journal-title":"Cancer"},{"key":"332_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5009\/gnl.2014.8.1.109","volume":"8","author":"HW Lee","year":"2014","unstructured":"Lee HW, Chung MJ, Kang H, et al. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature. Gut Liver. 2014;8:109\u201312.","journal-title":"Gut Liver"},{"key":"332_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2169\/internalmedicine.53.1160","volume":"53","author":"Y Yamada","year":"2014","unstructured":"Yamada Y, Suzuki K, Nobata H, et al. Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud\u2019s phenomenon, positive antinuclear antibodies and hypertensive emergency. Intern Med. 2014;53:445\u20138.","journal-title":"Intern Med"},{"key":"332_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/bjh.12718","volume":"164","author":"M Scully","year":"2014","unstructured":"Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164:759\u201366.","journal-title":"Br J Haematol"},{"key":"332_CR5","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","volume":"129","author":"TS Jokiranta","year":"2017","unstructured":"Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847\u201356.","journal-title":"Blood"},{"key":"332_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/bjh.12569","volume":"163","author":"N Shah","year":"2013","unstructured":"Shah N, Rutherford C, Matevosyan K, et al. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol. 2013;163:514\u20139.","journal-title":"Br J Haematol"},{"key":"332_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s10157-016-1276-6","volume":"20","author":"H Kato","year":"2016","unstructured":"Kato H, Nangaku M, Hataya H, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20:536\u201343.","journal-title":"Clin Exp Nephrol"},{"key":"332_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","volume":"91","author":"K Lechner","year":"2012","unstructured":"Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012;91:195\u2013205.","journal-title":"Medicine (Baltimore)"},{"key":"332_CR9","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","volume":"17","author":"JA Blake-Haskins","year":"2011","unstructured":"Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17:5858\u201366.","journal-title":"Clin Cancer Res"},{"key":"332_CR10","first-page":"32","volume":"23","author":"MR Green","year":"1996","unstructured":"Green MR. Gemcitabine safety overview. Semin Oncol. 1996;23:32\u20135.","journal-title":"Semin Oncol"},{"key":"332_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.12659\/AJCR.883583","volume":"13","author":"A Ata","year":"2012","unstructured":"Ata A, Gurses I, Kiykim A, et al. Nephrotic syndrome associated with gemcitabine use in a patient with ovarian cancer. Am J Case Rep. 2012;13:268\u201370.","journal-title":"Am J Case Rep"},{"key":"332_CR12","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.7754\/Clin.Lab.2016.160525","volume":"62","author":"J Usui","year":"2016","unstructured":"Usui J, Yokoyama C, Hagiwara M, et al. The detection of urinary podocytes from drug-induced glomerular thrombotic microangiopathy in advanced cancer patients. Clin Lab. 2016;62:2413\u20137.","journal-title":"Clin Lab"},{"key":"332_CR13","doi-asserted-by":"crossref","unstructured":"Brocklebank V, Wood K, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 2017; in press.","DOI":"10.2215\/CJN.00620117"},{"key":"332_CR14","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1681\/ASN.2013020134","volume":"24","author":"D Katagiri","year":"2013","unstructured":"Katagiri D, Hamasaki Y, Doi K, et al. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol. 2013;24:2034\u201343.","journal-title":"J Am Soc Nephrol"},{"key":"332_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ki.2015.327","volume":"89","author":"D Katagiri","year":"2015","unstructured":"Katagiri D, Hamasaki Y, Doi K, et al. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. Kidney Int. 2015;89:374\u201385.","journal-title":"Kidney Int"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-018-0332-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-018-0332-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-018-0332-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T20:16:28Z","timestamp":1557864988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-018-0332-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1007\/s13730-018-0332-3","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]},"assertion":[{"value":"20 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors have declared that no conflict of interest exists for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All of the treatment and the examination followed the guideline laid down in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Informed consent for the treatment and the renal biopsy was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}